Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer

Published:2018-05-01 Issue:5 Volume:4 Page:739
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Hong Shaodong¹²³,Gao Fangfang¹²³,Fu Sha⁴,Wang Yan⁵,Fang Wenfeng¹²³,Huang Yan¹²³,Zhang Li¹²³

Affiliation:

1. State Key Laboratory of Oncology in South China, Guangzhou

2. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

3. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

4. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Pathology Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

5. Quest Genomics, Nanjing, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer;Translational Oncology;2024-11

2. Genomic biology and therapeutic strategies of liver metastasis from gastric cancer;Critical Reviews in Oncology/Hematology;2024-10

3. A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer;Cancer Pathogenesis and Therapy;2024-06

4. Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study;Cancer Medicine;2024-04

5. MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study;Clinical and Translational Oncology;2024-03-02